Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 9 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Industry Foundation of Chonnam National University has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 examiners and 10 art units, creating broad distribution across the examination organization. The profile calls for structured docket control, consistent scientific terminology, and careful separation of issues by application and art unit.
SCHUBERG, LAURA J is the busiest examiner, with 2 pending matters. Those matters offer a defined opportunity to track recurring examiner issues, but the remaining assignments require broader portfolio coordination because examination is otherwise widely distributed.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| §102 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 7 (70%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHUBERG, LAURA J | 2 | 23.6% | +37.0% |
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
| FRASER, STEWART A | 1 | 86.0% | +14.4% |
| WELLES, COLMAN THOMAS | 1 | 26.9% | +65.7% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
| CONSTANTINE, CHARLES Z | 1 | 59.0% | +49.3% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 9d |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18710538 | COMPOSITION FOR PREVENTION OR TREATMENT OF MULTIPLE MYELOMA COMPRISING NOVEL TETRACYCLIC TRITERPENE COMPOUND AS ACTIVE INGREDIENT | CRAIGO, BAHAR ALAWI | — |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — |
| 18566110 | COMPOSITION CONTAINING FEEDER CELL FOR PROLIFERATING NATURAL KILLER CELL | SCHUBERG, LAURA J | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| 17775101 | SYNTHETIC ALPHA-SECRETASE AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 9d |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18710538 | COMPOSITION FOR PREVENTION OR TREATMENT OF MULTIPLE MYELOMA COMPRISING NOVEL TETRACYCLIC TRITERPENE COMPOUND AS ACTIVE INGREDIENT | CRAIGO, BAHAR ALAWI | — |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — |
| 18566110 | COMPOSITION CONTAINING FEEDER CELL FOR PROLIFERATING NATURAL KILLER CELL | SCHUBERG, LAURA J | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| 18030584 | NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1699 | 1 |
| 1724 | 1 |
| 1612 | 1 |
| 1645 | 1 |
| 1647 | 1 |
| 1657 | 1 |
| 1633 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710538 | COMPOSITION FOR PREVENTION OR TREATMENT OF MULTIPLE MYELOMA COMPRISING NOVEL TETRACYCLIC TRITERPENE COMPOUND AS ACTIVE INGREDIENT | CRAIGO, BAHAR ALAWI | 1699 | §102§103 | Non-Final OA | — | Pending | May 15, 2024 |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | 1724 | §102§103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18566110 | COMPOSITION CONTAINING FEEDER CELL FOR PROLIFERATING NATURAL KILLER CELL | SCHUBERG, LAURA J | 1631 | §102§103 | Final Rejection | — | Pending | Dec 01, 2023 |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | 1631 | §102 | Final Rejection | — | Pending | Oct 18, 2023 |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 1612 | §103§112 | Non-Final OA | 21d | Pending | Oct 02, 2023 |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | 1645 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18030584 | NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF | DEBERRY, REGINA M | 1647 | §102§103DP | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18002292 | SALMONELLA STRAIN FOR TREATING CANCER AND USE THEREOF | CONSTANTINE, CHARLES Z | 1657 | §103 | Final Rejection | — | Pending | Dec 19, 2022 |
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | 9d | Pending | Sep 16, 2022 |
| 17775101 | SYNTHETIC ALPHA-SECRETASE AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Final Rejection | — | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIndustry Foundation of Chonnam National University has 10 pending office actions as of October 2026, spread across 9 art units and 9 examiners.
Laura J Schuberg has the most, with 2 of Industry Foundation of Chonnam National University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
